Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
2.440
-0.160 (-6.15%)
Nov 20, 2026, 4:00 PM EST - Market closed
Anixa Biosciences Employees
Anixa Biosciences had 4 employees as of October 31, 2025. The number of employees decreased by 1 or 20.00% compared to the previous year. That makes Anixa Biosciences the 42,009th largest employer in the world and 6,586th in the United States.
Employees
4
Change (1Y)
-1
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$2,595,500
Market Cap
84.82M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Oct 31, 2025 | 4 | -1 | -20.00% | 4 | 0 |
| Oct 31, 2024 | 5 | 0 | - | 5 | 0 |
| Oct 31, 2023 | 5 | 0 | - | 4 | 1 |
| Oct 31, 2022 | 5 | 0 | - | 4 | 1 |
| Oct 31, 2021 | 5 | 1 | 25.00% | 4 | 1 |
| Oct 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Oct 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Molecular Partners AG | 134 |
| Innate Pharma | 120 |
| Nkarta | 103 |
| Upstream Bio | 75 |
| Zura Bio | 40 |
| TuHURA Biosciences | 22 |
| Equillium | 15 |
| Tiziana Life Sciences | 10 |
ANIX News
- 2 days ago - Anixa Biosciences granted patent for ovarian cancer vaccine - TheFly
- 2 days ago - Anixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine Technology - PRNewsWire
- 3 days ago - Anixa Biosciences to collaborate with Curia on upcoming Phase 2 trial - TheFly
- 3 days ago - Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial - PRNewsWire
- 17 days ago - Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026 - PRNewsWire
- 27 days ago - Anixa Biosciences completes treatment of fifth cohort in ovarian cancer trial - TheFly
- 27 days ago - Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 5 weeks ago - Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference - PRNewsWire